John D. Lee

Array ( [id] => 10444633 [patent_doc_number] => 20150329646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-19 [patent_title] => 'NOVEL DIAGNOSTIC AND THERAPEUTIC TARGET IN INFLAMMATORY AND/OR CARDIOVASCULAR DISEASES' [patent_app_type] => utility [patent_app_number] => 14/709305 [patent_app_country] => US [patent_app_date] => 2015-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 18386 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14709305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10334672 [patent_doc_number] => 20150219677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'Methods and Kits for Measuring Von Willebrand Factor' [patent_app_type] => utility [patent_app_number] => 14/692781 [patent_app_country] => US [patent_app_date] => 2015-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11187 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14692781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436126 [patent_doc_number] => 20170037148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'ANTIBODIES FOR THE PREVENTION OR THE TREATMENT OF BLEEDING EPISODES' [patent_app_type] => utility [patent_app_number] => 15/303889 [patent_app_country] => US [patent_app_date] => 2015-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14910 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15303889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10325746 [patent_doc_number] => 20150210749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'METHODS OF TREATMENT USING FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/686352 [patent_app_country] => US [patent_app_date] => 2015-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 60315 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14686352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10325775 [patent_doc_number] => 20150210778 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'ANTICOAGULANT ANTIDOTES' [patent_app_type] => utility [patent_app_number] => 14/684576 [patent_app_country] => US [patent_app_date] => 2015-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 20125 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14684576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10468587 [patent_doc_number] => 20150353603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-10 [patent_title] => 'ENDOMETRIOSIS CELL TARGETING PEPTIDE AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/683520 [patent_app_country] => US [patent_app_date] => 2015-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 17394 [patent_no_of_claims] => 62 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14683520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318586 [patent_doc_number] => 20150203590 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ANTIBODY COMPOSITIONS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 14/678562 [patent_app_country] => US [patent_app_date] => 2015-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30215 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14678562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949511 [patent_doc_number] => 20170253663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-07 [patent_title] => 'METHODS FOR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII' [patent_app_type] => utility [patent_app_number] => 15/319016 [patent_app_country] => US [patent_app_date] => 2015-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12602 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15319016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604121 [patent_doc_number] => 20170121422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'ANTIBODIES AGAINST HPA-1A' [patent_app_type] => utility [patent_app_number] => 15/300656 [patent_app_country] => US [patent_app_date] => 2015-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 24448 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15300656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10399444 [patent_doc_number] => 20150284453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-08 [patent_title] => 'METHOD OF PROTECTING CARDIAC FUNCTION' [patent_app_type] => utility [patent_app_number] => 14/670700 [patent_app_country] => US [patent_app_date] => 2015-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7913 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14670700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13196159 [patent_doc_number] => 10112989 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-10-30 [patent_title] => Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor [patent_app_type] => utility [patent_app_number] => 14/669025 [patent_app_country] => US [patent_app_date] => 2015-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 30 [patent_no_of_words] => 29794 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14669025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16304171 [patent_doc_number] => 10772942 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-15 [patent_title] => Lyophilized factor IX formulations [patent_app_type] => utility [patent_app_number] => 15/128951 [patent_app_country] => US [patent_app_date] => 2015-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 17448 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15128951 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10354984 [patent_doc_number] => 20150239989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE' [patent_app_type] => utility [patent_app_number] => 14/632557 [patent_app_country] => US [patent_app_date] => 2015-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 7209 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14632557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12009719 [patent_doc_number] => 09803024 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-31 [patent_title] => 'Anti-human PAI-1 antibody' [patent_app_type] => utility [patent_app_number] => 15/120257 [patent_app_country] => US [patent_app_date] => 2015-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 22780 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15120257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10381945 [patent_doc_number] => 20150266952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'ANTIBODIES TO OPGL' [patent_app_type] => utility [patent_app_number] => 14/621072 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 26509 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621072 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949513 [patent_doc_number] => 20170253664 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2017-09-07 [patent_title] => 'DUAL TARGETING OF TAFI AND PAI-1' [patent_app_type] => utility [patent_app_number] => 15/117027 [patent_app_country] => US [patent_app_date] => 2015-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14202 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15117027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11949513 [patent_doc_number] => 20170253664 [patent_country] => US [patent_kind] => A2 [patent_issue_date] => 2017-09-07 [patent_title] => 'DUAL TARGETING OF TAFI AND PAI-1' [patent_app_type] => utility [patent_app_number] => 15/117027 [patent_app_country] => US [patent_app_date] => 2015-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14202 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15117027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11270565 [patent_doc_number] => 20160333113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'ANTI-TISSUE FACTOR MONOCLONAL ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/111875 [patent_app_country] => US [patent_app_date] => 2015-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12397 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15111875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10070686 [patent_doc_number] => 09109030 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-08-18 [patent_title] => 'Epsigam fusion protein' [patent_app_type] => utility [patent_app_number] => 14/594003 [patent_app_country] => US [patent_app_date] => 2015-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8262 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14594003 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11499211 [patent_doc_number] => 20170073393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-16 [patent_title] => 'FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/110673 [patent_app_country] => US [patent_app_date] => 2015-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 79998 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15110673 [rel_patent_id] =>[rel_patent_doc_number] =>)